Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 5
1966 1
1978 1
1982 1
1986 1
1987 1
1989 2
1990 1
1991 2
1992 1
1994 2
1996 2
1997 1
1998 2
1999 5
2000 2
2001 4
2002 5
2003 5
2004 8
2005 11
2006 6
2007 12
2008 11
2009 7
2010 8
2011 10
2012 6
2013 8
2014 11
2015 9
2016 8
2017 10
2018 7
2019 8
2020 16
2021 20
2022 15
2023 23
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier C, Blue BJ, Brayer J, Chandrasekhar S, Grajales Cruz A, De Avila G, Elmariah H, Faramand R, Freeman C, Jain M, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Lee DH, et al. Among authors: de avila g. Blood Adv. 2023 Aug 22;7(16):4247-4257. doi: 10.1182/bloodadvances.2023009766. Blood Adv. 2023. PMID: 37307173 Free PMC article.
Ryanodine receptors as leak channels.
Guerrero-Hernández A, Ávila G, Rueda A. Guerrero-Hernández A, et al. Among authors: avila g. Eur J Pharmacol. 2014 Sep 15;739:26-38. doi: 10.1016/j.ejphar.2013.11.016. Epub 2013 Nov 28. Eur J Pharmacol. 2014. PMID: 24291096 Review.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Hashmi H, et al. Among authors: de avila g. Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283888. Online ahead of print. Haematologica. 2023. PMID: 37855036 Free article.
CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma.
Burger KL, Fernandez MR, Meads MB, Sudalagunta P, Oliveira PS, Renatino Canevarolo R, Alugubelli RR, Tungsevik A, De Avila G, Silva M, Graeter AI, Dai HA, Vincelette ND, Prabhu A, Magaletti D, Yang C, Li W, Kulkarni A, Hampton O, Koomen JM, Roush WR, Monastyrskyi A, Berglund AE, Silva AS, Cleveland JL, Shain KH. Burger KL, et al. Among authors: de avila g. Cancer Res. 2023 Dec 1;83(23):3901-3919. doi: 10.1158/0008-5472.CAN-22-2350. Cancer Res. 2023. PMID: 37702657 Free PMC article.
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Peres LC, et al. Among authors: de avila g. Blood Adv. 2024 Jan 9;8(1):251-259. doi: 10.1182/bloodadvances.2023010894. Blood Adv. 2024. PMID: 37855718 Free PMC article.
240 results